Marifarm d.o.o. is a pharmaceutical company that provides high-quality contract services and ensures effective communication with contract manufacturing partners at all work stages.

Marifarm

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Metric
Company Name	Marifarm	Kyowa Kirin Co., Ltd.
Symbol		4.15K
MSH ID	SI:MARIFARM	COM:KYOWAKIRIN
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Pharmaceuticals	Drug Manufacturers - General
Country	SI	JP
Stage
Employee Count		5.97K
Website	marifarm.si	kyowakirin.com
LinkedIn		kyowa-kirin-inc.--u.s.
Founders

Metric
Market Cap		11.07B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		2.95B
Revenue (LTM)
Revenue (NTM)
Gross Profit		2.14B
EBITDA		779.90M
Operating Income		639.20M
Net Income		541.47M
EPS		1.01
Diluted EPS		1.01
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.74
Operating Profit Margin		0.25
EBITDA Margin		0.26
Net Profit Margin		0.20
Return on Equity		0.12
Return on Assets		0.09
Return on Capital Employed		0.13

SI:MARIFARM

Marifarm

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		21.47
P/B Ratio		1.53
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		3.76
EV Multiple		16.23

Metric
Days Sales Outstanding		98.59
Days Payables Outstanding		327.25
Days Inventory Outstanding		228.53
Operating Cycle		326.81
Cash Conversion Cycle		29.05
Asset Turnover		0.44

Metric
Operating Cash Flow		770.65M
Free Cash Flow		551.55M
Cash Flow to Debt		14.20
Operating Cash Flow/Sales		0.26
Free Cash Flow Yield		0.05

Metric
Cash & Equivalents		2.69B
Accounts Receivable		-19.55M
Inventory		475.94M
Goodwill		936.71M
Debt to Capitalization		0.03
Debt to Assets
Current Ratio		4.38
Quick Ratio		3.93

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue		0.17
SG&A to Revenue		0.40